Skip to main content
Clinical Trials/NCT04149002
NCT04149002
Completed
N/A

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan (IP3) - The IMPaCT-IP3 Study

Duke University1 site in 1 country30 target enrollmentFebruary 1, 2020
ConditionsPreterm Birth

Overview

Phase
N/A
Intervention
Not specified
Conditions
Preterm Birth
Sponsor
Duke University
Enrollment
30
Locations
1
Primary Endpoint
Acceptability as Measured by Number of Participants Who Completed the Study
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to pilot an intervention that was developed to improve uptake and adhere to an Individualized Prematurity Prevention Plan (IP3) for preterm birth prevention. Non-Hispanic Black (NHB) women are at higher risk for preterm birth compared to other racial and ethnic groups. Building on qualitative data from NHB women with input from a multidisciplinary stakeholder group, a patient-centered intervention was developed to improve uptake and adherence to an IP3 in NHB women.

Detailed Description

The study team will pilot test the intervention via a pilot randomized controlled trial. 60 pregnant NHB women will be recruited who have a history of singleton preterm birth and are currently pregnant with a singleton gestation. Consenting participants will be randomized to the intervention or an active control. The intervention includes: 1) an informational narrated powerpoint presentation that reviews the logistical details of the IP3, 2) structured encouragement via text messages and 3) employment law education sheet. The powerpoints will also be available for review on our you-tube channel for intervention patients. The active control arm includes: 1) a narrated powerpoint describing the Duke Prematurity Prevention Program and 2) text messages with general pregnancy information (i.e. it is safe to take Tylenol in pregnancy). At study intake, we will collect demographic data (age, self-described race, pregnancy history, social history, pregnancy-related anxiety scale, interpersonal processes of care and maternal social support index. The team will collect feedback on the intervention based on an intake questionnaire and an exit interview. Information will also be collected on adherence to the IP3 based on review of the participant's medical record. The primary aim of the study is to evaluation feasibility and acceptability. These endpoints will be measured via enrollment and participant feedback during the exit interview.

Registry
clinicaltrials.gov
Start Date
February 1, 2020
End Date
April 1, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • self described race as Non-Hispanic Black
  • history of prior singleton preterm delivery (before 37 weeks gestation)
  • current singleton gestation

Exclusion Criteria

  • women with anomalous fetuses
  • age below 18\]
  • non-English speaking

Outcomes

Primary Outcomes

Acceptability as Measured by Number of Participants Who Completed the Study

Time Frame: study duration (approximately 14 months)

Completion target of 80% participants retained in study protocol.

Feasibility as Measured by Number of Recruited Eligible Patients Enrolled

Time Frame: study duration (approximately 14 months)

Enrollment target of 30% of eligible patients recruited.

Secondary Outcomes

  • IP3 Adherence as Measured by Number of Participants With Patient and EMR (Electronic Medical Record) Report of Medication Compliance(approximately 1 year)
  • Interpersonal Process of Care (IPC-18) at Protocol Completion - Communication Domain(protocol completion (approximately 1 year))
  • Change in Maternal Social Support Scale (MSSS)(baseline to protocol completion (approximately 1 year))
  • Number of Neonates Admitted to the Newborn Intensive Care Unit (NICU)(approximately 40 weeks)
  • Interpersonal Process of Care (IPC-18) at Protocol Completion - Interpersonal Style Domain(protocol completion (approximately 1 year))
  • Gestational Age at Delivery in Weeks(approximately 40 weeks)
  • Pregnancy Specific Anxiety (PSA)(baseline, 28 weeks)
  • Interpersonal Process of Care (IPC-18) at Protocol Completion - Decision Making Domain(protocol completion (approximately 1 year))
  • Length of Delivery Hospital Admission in Days(approximately 40 weeks)
  • Birth Weight in Grams(approximately 40 weeks)

Study Sites (1)

Loading locations...

Similar Trials